drugset
drugset / Trial / NCT06016010

Efficacy and Safety of USL for Dry Eye Disease

NCT06016010 ↗

Phase 2 Unknown 120 enrolled Chan-Sik Kim
RandomizedParallel-groupTriple-blindTreatment

Summary

The objective is to compare the USL and placebo in terms of efficacy and safety, and to determine the appropriate dosage.

Timeline

Start
2024-01-01
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Achyranthis Radix Extract Unknown 500 mg —

Indications

dry eye syndrome